EUVIMEDEUVIMED entdecken
Crossref

PD ‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B ‐cell lymphoma

Fumiya Wada iD, Kimimori Kamijo, Yoshimitsu Shimomura, Daisuke Yamashita, Shigeo Hara, Takayuki Ishikawa

Immunology · 2024

DOI: 10.1111/imm.13711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Fumiya Wada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The tumour microenvironment (TME), which is modulated after immune‐chemotherapy, is involved in tumour growth and metastasis. Programmed cell death 1 (PD‐1) expressed on tumour‐infiltrating non‐malignant cells plays an important role in the TME through the PD‐1/programmed cell death ligand 1 (PD‐L1) signalling pathway. However, its impact in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) remains unclear.

Methods

We conducted a retrospective study using tissue samples at relapse for patients with R/R DLBCL ( n = 45) and evaluated the clinical impact of PD‐1 expression on tumour‐infiltrating non‐malignant cells (microenvironmental PD‐1, mPD‐1). In addition, corresponding 27 samples at diagnosis were analysed to evaluate the changes in PD‐1/PD‐L1 expression in the TME after chemotherapy.

Results

Patients with mPD‐1 + DLBCL showed significantly better overall survival compared with patients with mPD‐1 − DLBCL (hazard ratio, 0.30, p = 0.03). Among patients with mPD‐1 − DLBCL, those positive for neoplastic or microenvironmental PD‐L1 (nPD‐L1 + or mPD‐L1 + ) showed significantly worse outcomes. Microenvironmental PD‐1 and PD‐L1 expression has high correlation at relapse, although none was found at diagnosis.

Conclusion

We determined the clinical impact of microenvironmental PD‐1 expression and its relationship with neoplastic or microenvironmental expression of PD‐L1 in patients with R/R DLBCL. The expression of PD‐1 and PD‐L1 in the TME dramatically changes during the chemotherapy. Therefore, evaluating TME at relapse, not at diagnosis is useful to predict the outcomes of R/R DLBCL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLymphoma, Large B-Cell, DiffuseHumansPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesNeoplasm Recurrence, LocalRecurrenceTumor Microenvironment

Stichwörter der Autor:innen

cancerimmunotherapylymphoid architecturetumour immunology

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan.

ORCID-Profile: Fumiya Wada

Zitieren

APA

Wada, F., Kamijo, K., Shimomura, Y., Yamashita, D., Hara, S., & Ishikawa, T. (2024). PD ‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B ‐cell lymphoma. Immunology. https://doi.org/10.1111/imm.13711

Vancouver

Wada F, Kamijo K, Shimomura Y, Yamashita D, Hara S, Ishikawa T. PD ‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B ‐cell lymphoma. Immunology. 2024. doi:10.1111/imm.13711

BibTeX
@article{Wada2024,
  author = {Wada, Fumiya and Kamijo, Kimimori and Shimomura, Yoshimitsu and Yamashita, Daisuke and Hara, Shigeo and Ishikawa, Takayuki},
  title = {PD ‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B ‐cell lymphoma},
  journal = {Immunology},
  year = {2024},
  doi = {10.1111/imm.13711}
}
Kostenlos starten →